Business
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Expansion Adds to Growing Global Trial FootprintPatient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study
About this update from Allogene Therapeutics, Inc.
[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fF5s8tDZfOcdddQ1DBkmiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3Ng--/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expansion Adds to Growing Global Trial Footprint","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Patient Screening and Enrollment Expected to Begin in Q2 2026","length":61,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":109,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that regulatory authorities in South Korea and Australia have cleared the Company to expand its pivotal Phase 2 ALPHA3 study evaluating cemacabtagene ansegedleucel (cema-cel) in first-line (1L) consolidation treatment for patients with large B-cell lymphoma (LBCL).","length":531,"tagName":"p"},{"type":"text","content":"The study, currently enrolling across more than 60 sites in North America, will expand to over 80 global sites with the addition of South Korea and Australia. This growing trial footprint reflects strong interest in ALPHA3 from clinical trial sites.","length":249,"tagName":"p"},{"type":"text","content":"“Expanding into South Korea and Australia allows us to leverage regions with established clinical research infrastructure and experienced investigators,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “These countries provide high-quality trial environments and efficient healthcare delivery systems. These regulatory approvals, follow our recent interim futility analysis, and we expect this expansion to support the continued enrollment and global development of cema-cel.”The Company recently announced findings from a planned interim futility analysis of the AL...